Baxter Sigma Spectrum Infusion Pump with master Drug Library — Class II medical device recall Z-1663-2018
Terminated recall by Baxter Healthcare Corporation, reported 2018-05-16, distributed nationwide. Service technician improperly documented final release testing on product, indicating that the full battery of
| Recall number | Z-1663-2018 |
|---|---|
| Product type | Medical device |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Baxter Healthcare Corporation, Medina, NY, United States |
| Recall initiated | 2018-04-03 |
| Classified | 2018-05-04 |
| Reported by FDA | 2018-05-16 |
| Terminated | 2020-02-14 |
| Distributed | Nationwide (US) |
| Quantity | 444 units |
| Reason classes | device malfunction |
| Serial numbers | 1000562, 1000614, 1000881, 1001843, 1002586, 1013602, 400792, 402108, 718349, 719336, 720207, 724491, 724820, 725718, 725967, 728874, 728899, 732513, 734021, 734895, 736505, 737537, 743970, 745479, 745645 and 209 more |
Product
Baxter Sigma Spectrum Infusion Pump with master Drug Library (Version 6) 35700BAX Product Usage: The Baxter Sigma Spectrum Infusion Pump with master Drug Library is intended to be used for the controlled administration of fluids. These fluids may includes pharmaceutical drugs, blood, blood products and mixture if required patient therapy. The intended routes of administration consist of the following clinically accepted routes: intravenous, arterial, subcutaneous, intrathecal, epidural or irrigation of fluids. Spectrum infusion pump is intended to be used in conjunction with legally marketed intravenous administration sets and medications provided by user. The Spectrum and Spectrum with MAster Drug Library is intended to reduce operator interaction through automated programming thereby helping to reduce errors associated with complex device programming.
Reason for recall
Service technician improperly documented final release testing on product, indicating that the full battery of release tests were performed when, in fact, several tests were omitted. he omitted tests include air-in-line detection at 400ml/hr and 800ml/hr and verification of upstream occlusion detection at 800ml/hr. Improper detection of air-in-line or upstream occlusion may result in serious adverse health consequences.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-1663-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.